Astrazeneca Ab Company Profile

What is the competitive landscape for ASTRAZENECA AB

ASTRAZENECA AB has twelve approved drugs.

There are forty-five US patents protecting ASTRAZENECA AB drugs. There is one tentative approval on ASTRAZENECA AB drugs.

There are nine hundred and twenty-six patent family members on ASTRAZENECA AB drugs in fifty-four countries and one hundred and thirty-seven supplementary protection certificates in nineteen countries.

Summary for Astrazeneca Ab

International Patents:	926
US Patents:	45
Tradenames:	13
Ingredients:	10
NDAs:	12
Drug Master File Entries:	2
Patent Litigation for Astrazeneca Ab:	See patent lawsuits for Astrazeneca Ab
PTAB Cases with Astrazeneca Ab as patent owner:	See PTAB cases with Astrazeneca Ab as patent owner

Drugs and US Patents for Astrazeneca Ab

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		DISCN	Yes	No	7,456,254*PED				Y
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		DISCN	Yes	No	9,320,853*PED				Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-005	Jul 28, 2017		RX	Yes	No

Expired US Patents for Astrazeneca Ab

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017	6,936,590
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014	6,936,590
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	9,238,076
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-002	May 2, 2019	9,198,925

Paragraph IV (Patent) Challenges for ASTRAZENECA AB drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	5 mg/500 mg, 2.5 mg/1000 mg, and 5 mg/1000 mg		2013-07-31
	Tablets	2.5 mg and 5 mg		2013-07-31
	Injection	250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe		2014-06-11
	HydrochlorideExtended-release Tablets	2.5 mg/1000 mg		2018-10-29

International Patents for Astrazeneca Ab Drugs

Country	Patent Number	Estimated Expiration
Denmark	2144649
Hong Kong	1205689
South Korea	20230006933
Taiwan	I478746

Supplementary Protection Certificates for Astrazeneca Ab Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2498758	2020C/509	Belgium		PRODUCT NAME: QTRILMET - METFORMINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; SAXAGLIPTINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; DAPAGLIFLOZINE OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1401 20191113
1734971	C01734971/01	Switzerland		PRODUCT NAME: EXENATIDE; REGISTRATION NO/DATE: SWISSMEDIC 61629 17.02.2012
1532149	C300569	Netherlands		PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN COMBINATIE MET METFORMINEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/12/780/001-028 20120720
1506211	CA 2014 00037	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Astral
• Astrazeneca
• Astrazeneca Ab
• Astrazeneca Lp

Pharmaceutical Competitive Landscape Analysis: AstraZeneca AB – Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceuticals, AstraZeneca AB stands as a formidable player, consistently pushing the boundaries of innovation and market dominance. This comprehensive analysis delves into AstraZeneca's market position, strengths, and strategic insights, offering a panoramic view of the company's competitive landscape.

AstraZeneca's Market Position

AstraZeneca has firmly established itself as a global leader in the pharmaceutical industry. With a strong presence in over 100 countries, the company has strategically positioned itself to cater to diverse healthcare needs worldwide[2].

Revenue Growth and Market Share

AstraZeneca's market position is reflected in its impressive revenue growth. In 2023, the company reported total revenue of $45.8 billion, marking a significant increase from previous years[1]. This robust financial performance underscores AstraZeneca's growing market share and competitive edge.

"Today AstraZeneca announces a new era of growth. In 2023 we delivered the ambitious $45 billion revenue goal set a decade ago. With the exciting growth of our innovative pipeline, which has the potential to transform millions of lives, we are now aiming for $80 billion by 2030." - Pascal Soriot, Chief Executive Officer, AstraZeneca[1]

Therapeutic Areas of Dominance

AstraZeneca's market position is particularly strong in key therapeutic areas:

1. Oncology: With $16.4 billion in revenue and a 12.7% global market share in 2022[7].
2. Cardiovascular: Generating $7.2 billion in revenue with an 8.5% market share[7].
3. Respiratory: Achieving $5.9 billion in revenue and holding a 10.3% market share[7].

These figures highlight AstraZeneca's significant presence in critical healthcare segments, positioning the company as a key player in addressing major global health challenges.

Strengths Driving AstraZeneca's Competitive Edge

Robust Research and Development

AstraZeneca's commitment to innovation is evident in its substantial investment in research and development (R&D). In 2022, the company invested $7.1 billion in R&D, demonstrating its dedication to advancing medical science[7].

Pipeline Strength

The company's R&D efforts have resulted in an impressive pipeline:

• Over 180 ongoing clinical trials
• 70+ molecules in clinical development
• 15 potential launch candidates by 2025[7]

This robust pipeline not only ensures a steady stream of innovative products but also positions AstraZeneca at the forefront of addressing unmet medical needs.

Global Reach and Market Penetration

AstraZeneca's global footprint is a significant strength, allowing the company to tap into diverse markets and patient populations. The company's revenue distribution across regions showcases its global market penetration:

• United States: 44.2%
• Europe: 28.6%
• Asia-Pacific: 19.5%
• Rest of World: 7.7%[7]

This widespread presence enables AstraZeneca to mitigate risks associated with regional market fluctuations and capitalize on growth opportunities in emerging markets.

Strategic Partnerships and Collaborations

AstraZeneca has forged strategic alliances with leading academic institutions, research organizations, and other pharmaceutical companies. These partnerships enhance the company's capabilities in drug discovery and development, fostering innovation and driving competitive advantage[4].

Notable collaborations include:

• Regeneron Pharmaceuticals in oncology
• Daiichi Sankyo in cancer therapeutics
• Cambridge University for research alliance[7]

These partnerships not only expand AstraZeneca's research capabilities but also provide access to complementary technologies and expertise.

Strategic Insights: AstraZeneca's Path to Future Growth

Focus on Precision Medicine and Digital Health

AstraZeneca is strategically investing in precision medicine and digital health technologies to stay ahead of the curve. In 2022, the company invested:

• $625 million in AI-driven drug discovery
• $412 million in digital diagnostic platforms[7]

This focus on cutting-edge technologies positions AstraZeneca to deliver more personalized and effective treatments, potentially revolutionizing patient care.

Expansion in Emerging Markets

Recognizing the growth potential in emerging markets, AstraZeneca is strategically expanding its presence in these regions. Key markets showing significant healthcare investment growth include:

• China: 8.7% annual growth
• India: 7.5% annual growth
• Brazil: 5.3% annual growth[7]

By tapping into these rapidly growing markets, AstraZeneca is positioning itself for sustained long-term growth.

Leveraging COVID-19 Expertise

AstraZeneca's role in developing a COVID-19 vaccine has not only contributed to global health efforts but also positioned the company as a key player in infectious disease prevention. The company's COVID-19 vaccine achievements include:

• 2.9 billion doses distributed globally
• $8.32 billion in vaccine revenue in 2021[7]

This experience and infrastructure can be leveraged for future vaccine development and pandemic preparedness initiatives.

Competitive Landscape: AstraZeneca vs. Industry Peers

Market Share Comparison

When compared to its major competitors, AstraZeneca holds a strong position in key therapeutic areas:

Company	Oncology Market Share	Cardiovascular Market Share	Respiratory Market Share
AstraZeneca	12.7%	8.5%	10.3%
Competitor A	11.2%	7.8%	9.1%
Competitor B	10.5%	9.2%	8.7%

Note: Competitor data is hypothetical for illustration purposes

R&D Investment Comparison

AstraZeneca's commitment to R&D is evident when compared to industry averages:

AstraZeneca spends well above 20 percent – in some years even nearly 30 percent – of its revenues on R&D projects[10].

This level of investment surpasses many industry peers, positioning AstraZeneca as a leader in innovation.

Future Outlook and Growth Projections

AstraZeneca's future looks promising, with the company setting ambitious growth targets:

• Aim to deliver $80 billion in Total Revenue by 2030[1]
• Plans to launch 20 new medicines by 2030[1]
• Targeting at least mid-30s percentage Core operating margin beyond 2026[1]

These projections, coupled with the company's strong pipeline and strategic initiatives, suggest a trajectory of continued growth and market leadership.

Challenges and Potential Threats

Despite its strong position, AstraZeneca faces several challenges:

1. Patent Expirations: Like all pharmaceutical companies, AstraZeneca must navigate the loss of exclusivity for key products[3].
2. Pricing Pressures: Increasing scrutiny on drug pricing globally could impact profit margins[3].
3. Intense Competition: The pharmaceutical industry remains highly competitive, with rivals constantly innovating[2].
4. Regulatory Hurdles: Stringent and evolving regulatory requirements pose ongoing challenges[3].

Addressing these challenges will be crucial for AstraZeneca to maintain its competitive edge and achieve its ambitious growth targets.

Key Takeaways

1. AstraZeneca holds a strong market position with $45.8 billion in revenue in 2023 and aims for $80 billion by 2030.
2. The company's strengths lie in its robust R&D investment, global reach, and strategic partnerships.
3. AstraZeneca is focusing on precision medicine, digital health, and emerging markets for future growth.
4. The company's experience with COVID-19 vaccine development positions it well for future infectious disease challenges.
5. While facing challenges like patent expirations and pricing pressures, AstraZeneca's strong pipeline and strategic initiatives suggest a positive growth trajectory.

FAQs

1. Q: What are AstraZeneca's main therapeutic areas of focus? A: AstraZeneca primarily focuses on oncology, cardiovascular, and respiratory diseases, with significant market shares in each of these areas.

2. Q: How much does AstraZeneca invest in Research and Development? A: In 2022, AstraZeneca invested $7.1 billion in R&D, which represents over 20% of its revenues.

3. Q: What is AstraZeneca's strategy for growth in emerging markets? A: AstraZeneca is expanding its presence in rapidly growing markets like China, India, and Brazil, capitalizing on increasing healthcare investments in these regions.

4. Q: How is AstraZeneca leveraging digital technologies in its operations? A: AstraZeneca is investing heavily in AI-driven drug discovery and digital diagnostic platforms, with $625 million and $412 million invested respectively in 2022.

5. Q: What are AstraZeneca's revenue projections for the future? A: AstraZeneca aims to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023.

Sources cited:

1. https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-deliver-80bn-revenue-by-2030.html
2. https://canvasbusinessmodel.com/blogs/competitors/astrazeneca-competitive-landscape
3. https://www.studentsassignmenthelp.co.uk/answers/astrazeneca-uk-swot-analysis/
4. https://canvasbusinessmodel.com/blogs/growth-strategy/astrazeneca-growth-strategy
5. https://www.astrazeneca.com/content/dam/az/PDF/2023/fy/Full-year-and-Q4-2023-results-announcement.pdf
6. https://dcfmodeling.com/products/azn-swot-analysis
7. https://www.statista.com/topics/7584/astrazeneca/